All In Biotech

Drug Trial Radar · NCT07362030

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin

A Open-Label, Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

32

Actual

Start

Apr 14, 2025

Primary completion

Dec 27, 2025

Study completion Mar 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The drug-drug interaction study had been designed to investigate the effect of RAY1225 on the pharmacokinetics of digoxin, Rosuvastatin and

Conditions

  • Obesity

Interventions

  • RAY1225Drug

    subcutaneous injection

  • atorvastatin calcium tabletDrug

    Oral

  • Metformin TabletsDrug

    Oral

  • Warfarin Sodium TabletsDrug

    Oral

  • Digoxin TabletsDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic - CmaxTime frame: Day 1~Day 5 and Day 86~Day 107
  2. Pharmacokinetic -Area under the curve(AUC)Time frame: Day 1~Day 5 and Day 86~Day 107

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dongguan People's Hospital

    Dongguan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.